Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Lenalidomide/pomalidomide/thalidomide

Lenalidomide/pomalidomide/thalidomide Reactions 1704, p220 - 2 Jun 2018 Lenalidomide/pomalidomide/ thalidomide Deep vein thrombosis, pulmonary emboism and venous thromboembolism: 5 case reports In a study, 5 patients [ages not stated and not all sexes stated] were described, out of whom one man developed deep vein thrombosis (DVT) on pomalidomide, two patients developed venous thromboembolism (VTE) during treatment with thalidomide, and two patients developed VTE and pulmonary embolism (PE) or DVT during treatment with lenalidomide [routes, dosages and outcomes not stated]. Patient 1: The patient developed VTE complicated by pulmonary embolism during treatment with lenalidomide. The patient was started on lenalidomide for myeloma. Since cycle 3, the patient was commenced on aspirin as thromboembolism prophylaxis; however, the patient subsequently developed VTE complicated by pulmonary embolism at cycle 25. Patient 2: The patient developed VTE complicated by DVT during treatment with lenalidomide. The patient was started on lenalidomide for myeloma and enoxaparin sodium [enoxaparin] as thromboembolism prophylaxis. The patient discontinued enoxaparin sodium at cycle 6 and subsequently developed VTE complicated by DVT at cycle 9. Patient 3: The patient developed VTE during treatment with thalidomide. The patient was started on thalidomide for myeloma and aspirin as thromboembolism prophylaxis. At cycle 2, the patient http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Lenalidomide/pomalidomide/thalidomide

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Download PDF
1 page

Lenalidomide/pomalidomide/thalidomide

Abstract

Reactions 1704, p220 - 2 Jun 2018 Lenalidomide/pomalidomide/ thalidomide Deep vein thrombosis, pulmonary emboism and venous thromboembolism: 5 case reports In a study, 5 patients [ages not stated and not all sexes stated] were described, out of whom one man developed deep vein thrombosis (DVT) on pomalidomide, two patients developed venous thromboembolism (VTE) during treatment with thalidomide, and two patients developed VTE and pulmonary embolism (PE) or DVT during treatment with...
Loading next page...
 
/lp/springer-journals/lenalidomide-pomalidomide-thalidomide-lF58H3kX3s
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46863-2
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p220 - 2 Jun 2018 Lenalidomide/pomalidomide/ thalidomide Deep vein thrombosis, pulmonary emboism and venous thromboembolism: 5 case reports In a study, 5 patients [ages not stated and not all sexes stated] were described, out of whom one man developed deep vein thrombosis (DVT) on pomalidomide, two patients developed venous thromboembolism (VTE) during treatment with thalidomide, and two patients developed VTE and pulmonary embolism (PE) or DVT during treatment with lenalidomide [routes, dosages and outcomes not stated]. Patient 1: The patient developed VTE complicated by pulmonary embolism during treatment with lenalidomide. The patient was started on lenalidomide for myeloma. Since cycle 3, the patient was commenced on aspirin as thromboembolism prophylaxis; however, the patient subsequently developed VTE complicated by pulmonary embolism at cycle 25. Patient 2: The patient developed VTE complicated by DVT during treatment with lenalidomide. The patient was started on lenalidomide for myeloma and enoxaparin sodium [enoxaparin] as thromboembolism prophylaxis. The patient discontinued enoxaparin sodium at cycle 6 and subsequently developed VTE complicated by DVT at cycle 9. Patient 3: The patient developed VTE during treatment with thalidomide. The patient was started on thalidomide for myeloma and aspirin as thromboembolism prophylaxis. At cycle 2, the patient

Journal

Reactions Weekly – Springer Journals

Published: Jun 2, 2018

There are no references for this article.